ClinicalTrials.gg
RecruitingNCT07491185NIRS-DMUpdated Nov 12, 2026

Effect of Glycemic Control on Intraoperative NIRS and Postoperative Recovery in Diabetic Patients

An observational study in Diabetes Mellitus, Glycemic Control and Cerebral Oxygenation, sponsored by Ege University. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Ege University · Observational

How we know

From the registry’s dates

  • Started Nov 2025; still recruiting 1 year later.
Updated Nov 12, 2026Primary completion moved1 site added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
80
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 246 studies in Diabetes Mellitus with a site in Turkey — 37 open to participants now, 44 under way, 1 of them phase 3. Diabetes Mellitus · Turkey.

Planned enrollment
70th of 97
80 · median 120
Started
2025
with 21 others
Observational
97 of 246
14 open now
Primary completion
2026-11
later than 33 of 43 live
Registered
234th of 246
by date

Among the 246 studies in Diabetes Mellitus with a site in Turkey, this one is the 70th largest by planned enrollment of the 97 observational ones that give a count, is one of 22 that started in 2025, is one of 97 observational ones, reaches primary completion later than 33 of the 43 other live ones, and was the 234th registered.

Diabetes Mellitus

8,295 studies on the registry are indexed under Diabetes Mellitus; 1,071 are open to participants now.

Browse Diabetes Mellitus studies →

Open to participants now

37 of the 246 studies in Diabetes Mellitus with a site in Turkey are open now. Recruiting first, the newest first:

31 more — sign in →

All 37 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 649 Diabetes Mellitus studies recruiting now, 358 (55%) set no upper age limit and 194 (30%) stop at 75 or younger; 89 take children under 18; 181 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 246 studies in Diabetes Mellitus with a site in Turkey, or all of them as a file.
02

Study summary

This prospective observational study aims to evaluate the effect of glycemic control level on intraoperative cerebral oxygenation measured by near-infrared spectroscopy (NIRS) and postoperative recovery in patients with diabetes mellitus undergoing elective urologic surgery under general anesthesia.

Patients will be grouped according to HbA1c levels to assess the relationship between long-term glycemic control and intraoperative regional cerebral oxygen saturation, hemodynamic parameters, and postoperative recovery scores.

Read the detailed description

Diabetes mellitus is associated with increased perioperative morbidity and mortality, particularly in patients with poor long-term glycemic control. Elevated HbA1c levels may impair microcirculation and tissue oxygenation, which can affect cerebral perfusion during general anesthesia. Near-infrared spectroscopy (NIRS) is a non-invasive monitoring technique that allows continuous measurement of regional cerebral oxygen saturation and may help detect intraoperative hypoperfusion.

This prospective observational study is designed to investigate the relationship between glycemic control level and intraoperative cerebral oxygenation as well as postoperative recovery parameters in patients undergoing elective urologic surgery under general anesthesia. Patients will be divided into four groups according to preoperative HbA1c levels, including non-diabetic patients and diabetic patients with different levels of glycemic control.

Intraoperative monitoring will include standard hemodynamic parameters and bilateral regional cerebral oxygen saturation measured with near-infrared spectroscopy. The primary objective of the study is to determine whether poor glycemic control is associated with impaired cerebral oxygenation during anesthesia. Secondary objectives include evaluation of postoperative recovery parameters in relation to glycemic control level.

03

Conditions studied

  • Diabetes Mellitus
  • Glycemic Control
  • Cerebral Oxygenation
  • Anesthesia

Browse trials for

Keywords

  • Diabetes Mellitus
  • Glycemic Control
  • Near-Infrared Spectroscopy
  • Postoperative Recovery
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult patients scheduled for elective urologic surgery under general anesthesia at a single tertiary university hospital will be included. The study population consists of patients with diabetes mellitus with different levels of glycemic control and non-diabetic control patients. Participants will be grouped according to preoperative HbA1c levels.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years
  • Patients scheduled for elective urologic surgery under general anesthesia
  • I-III
  • Patients with diabetes mellitus or non-diabetic control patients
  • Availability of preoperative measurement
  • Written obtained

Exclusion criteria

Exclusion Criteria:

  • Age \<18 years
  • >III
  • Emergency surgery
  • History of cerebrovascular disease or neurological disorder
  • Previous brain or neurological surgery
  • Inability to communicate or refusal to participate
  • Intraoperative hemodynamic instability
  • Inadequate NIRS monitoring data
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
80 participants (estimated)
Patient registry
No

Groups and cohorts

  • Control

    Non-diabetic patients

  • HbA1c 6-7

    Diabetic patients with HbA1c between 6% and 7%

  • HbA1c 7-8

    Diabetic patients with HbA1c between 7% and 8%

  • HbA1c >8

    Diabetic patients with HbA1c greater than 8%

06

What researchers measure

Primary outcomes

  1. Change in Regional Cerebral Oxygen Saturation (rSO2)

    Regional cerebral oxygen saturation measured intraoperatively using near-infrared spectroscopy and compared between groups according to HbA1c level.

    Time frame: Intraoperative period (from anesthesia induction to extubation)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Individual participant data will not be shared due to institutional regulations and privacy restrictions.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Nov 2026, 12 months after the start.

Of 534 non-industry observational studies under Diabetes Mellitus, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 159. This study's planned 12 months is below that.

Counting every sponsor, half of 643 studies reached it within 36 months; a quarter within 14 and three quarters within 122.

Primary completion moved once since we started tracking on Sep 25, 2026: Sep 2026 → Nov 2026, on Nov 12, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 18, 2026
First posted
Mar 24, 2026
StartActual
Nov 1, 2025
Primary completionEst.
Nov 2026was Sep 2026
CompletionEst.
Mar 2027
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed
Show site
  • Ege University Faculty of Medicine Hospital · Izmir, Turkey (Türkiye)
Show 1 removed
  • Ege University Faculty of Medicine Hospital · Izmir, Turkey (Türkiye)
Nov 12, 2026
Primary completion
Sep 2026→Nov 2026
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    1 site added, 1 site removed
    Show site
    • Ege University Faculty of Medicine Hospital · Izmir, Turkey (Türkiye)
    Show 1 removed
    • Ege University Faculty of Medicine Hospital · Izmir, Turkey (Türkiye)
    Primary completion Sep 2026→Nov 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07491185
Lead sponsor
Ege University
Responsible party
Nursen Karaca (MD, Ege University) — Principal investigator
First posted
Mar 24, 2026
Start date
Nov 1, 2025
Primary completion
Nov 2026 (estimated)
Completion
Mar 2027 (estimated)
Last update
Nov 12, 2026

Study contacts

Nursen Karaca, MD
Contact
dr.nursenkaraca@hotmail.com
+902323902142 ext. 2142
Işık Alper, Professor
Contact
i.alper@yahoo.com
+902323902140 ext. 2140
NURSEN KARACA, MD
principal investigator · Ege University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion